Articles producció científica> Medicina i Cirurgia

Secretory Phospholipase A2-IIA and Cardiovascular Disease: A Mendelian Randomization Study.

  • Dades identificatives

    Identificador: PC:515
    Autors:
    Holmes, M.V.Simon, T.Exeter, H.JFolkersen, L.Asselbergs, F.W.Guardiola, M.Cooper, J.A.Palmen, J.Hubacek, J.A.Carruthers, K.F.Horne, B.D.Brunisholz, K.D.Mega, J.L.Van Iperen, E.P.Li, M.Leusink, M.Trompet, S.Verschuren, J.J.Hovingh, G.K.Dehghan, A.Nelson, C.P.Kotti, S.Danchin, N.Scholz, M.Haase, C.L.Rothenbacher, D.Swerdlow, D.I.Kuchenbaecker, K.B.Staines-Urias, E.Goel, A.Van 't Hooft, F.Gertow, K.De Faire, U.Panayiotou, A.G.Tremoli, E., Baldassarre, D.Veglia, F.Holdt, L.M.Beutner, F.Gansevoort. R.T.Navis, G.J.Mateo, L.I.Breitling, L.P.Brenner, H.Thiery, J.Dallmeier, D.Franco-Cereceda, A.Boer, J.M.Stephens, J.W.Hofker, M.H.Tedgui, A.Hofman, A.Uitterlinden, A.G.Adamkova, V.Pitha, J.Onland-Moret, N.C.Cramer, M.J.Nathoe, H.M.Spiering, W.Klungel, O.H.Kumari, M.Whincup, P.H.Morrow, D.A.Braund, P.S.Hall, A.S.Olsson, A.G.Doevendans, P.A.Trip, M.D.Tobin, M.D.Hamsten, A.Watkins, H.Koenig, W.Nicolaides, A.N.Teupser, D.Day, I.N.Carlquist, J.F.Gaunt, T.R.Ford, I.Sattar, N.Tsimikas, S.Schwartz, G.G.Lawlor, D.A.Morris, R.W.Sandhu, M.S.Poledne, R.Maitland-van der Zee, A.H.Khaw, K.T.Keating, B.J.Van der Harst, P.Price, J.F.Mehta, S.R.Yusuf, S.Witteman, J.C.Franco, O.H.Jukema, J.W.De Knijff, P.Tybjaerg-Hansen, A.Rader, D.J.Farrall, M.Samani, N.J.Kivimaki, M.Fox, K.A.Humphries, S.E.Anderson, J.L.Boekholdt, S.M.Palmer, T.M.Eriksson, P.Paré, G.Hingorani, A.D.Sabatine, M.S.Mallat, Z.Casas, J.P.Talmud, P.J.
    Resum:
    This study sought to investigate the role of secretory phospholipase A2(sPLA2)-IIA in cardiovascular disease. Higher circulating levels of sPLA2-IIA mass or sPLA2enzyme activity have been associated with increased risk ofcardiovascular events. However, it is not clear if this association is causal. A recent phase III clinical trial of an sPLA2inhibitor (varespladib) was stopped prematurely for lack of efficacy
  • Altres:

    Autor segons l'article: Holmes, M.V. Simon, T. Exeter, H.J Folkersen, L. Asselbergs, F.W. Guardiola, M. Cooper, J.A. Palmen, J. Hubacek, J.A. Carruthers, K.F. Horne, B.D. Brunisholz, K.D. Mega, J.L. Van Iperen, E.P. Li, M. Leusink, M. Trompet, S. Verschuren, J.J. Hovingh, G.K. Dehghan, A. Nelson, C.P. Kotti, S. Danchin, N. Scholz, M. Haase, C.L. Rothenbacher, D. Swerdlow, D.I. Kuchenbaecker, K.B. Staines-Urias, E. Goel, A. Van 't Hooft, F. Gertow, K. De Faire, U. Panayiotou, A.G. Tremoli, E., Baldassarre, D. Veglia, F. Holdt, L.M. Beutner, F. Gansevoort. R.T. Navis, G.J. Mateo, L.I. Breitling, L.P. Brenner, H. Thiery, J. Dallmeier, D. Franco-Cereceda, A. Boer, J.M. Stephens, J.W. Hofker, M.H. Tedgui, A. Hofman, A. Uitterlinden, A.G. Adamkova, V. Pitha, J. Onland-Moret, N.C. Cramer, M.J. Nathoe, H.M. Spiering, W. Klungel, O.H. Kumari, M. Whincup, P.H. Morrow, D.A. Braund, P.S. Hall, A.S. Olsson, A.G. Doevendans, P.A. Trip, M.D. Tobin, M.D. Hamsten, A. Watkins, H. Koenig, W. Nicolaides, A.N. Teupser, D. Day, I.N. Carlquist, J.F. Gaunt, T.R. Ford, I. Sattar, N. Tsimikas, S. Schwartz, G.G. Lawlor, D.A. Morris, R.W. Sandhu, M.S. Poledne, R. Maitland-van der Zee, A.H. Khaw, K.T. Keating, B.J. Van der Harst, P. Price, J.F. Mehta, S.R. Yusuf, S. Witteman, J.C. Franco, O.H. Jukema, J.W. De Knijff, P. Tybjaerg-Hansen, A. Rader, D.J. Farrall, M. Samani, N.J. Kivimaki, M. Fox, K.A. Humphries, S.E. Anderson, J.L. Boekholdt, S.M. Palmer, T.M. Eriksson, P. Paré, G. Hingorani, A.D. Sabatine, M.S. Mallat, Z. Casas, J.P. Talmud, P.J.
    Departament: Medicina i Cirurgia
    e-ISSN: 1558-3597
    Autor/s de la URV: Guardiola, M. Michael V Holmes, Lasse Folkersen, Tabassome Simon
    Paraules clau: Cardiovascular diseases; Drug development; Epidemiology; Genetics; Mendelian randomization
    Resum: This study sought to investigate the role of secretory phospholipase A2(sPLA2)-IIA in cardiovascular disease. Higher circulating levels of sPLA2-IIA mass or sPLA2enzyme activity have been associated with increased risk ofcardiovascular events. However, it is not clear if this association is causal. A recent phase III clinical trial of an sPLA2inhibitor (varespladib) was stopped prematurely for lack of efficacy
    Accès a la llicència d'ús: https://creativecommons.org/licenses/by/3.0/es/
    ISSN: 0735-1097
    Pàgina final: 1976
    Volum de revista: 62
    Versió de l'article dipositat: info:eu-repo/semantics/publishedVersion
    Enllaç font original: https://www.sciencedirect.com/science/article/pii/S0735109713027782?via%3Dihub
    URL Document de llicència: https://repositori.urv.cat/ca/proteccio-de-dades/
    DOI de l'article: https://doi.org/10.1016/j.jacc.2013.06.044
    Entitat: Universitat Rovira i Virgili.
    Any de publicació de la revista: 2013
    Pàgina inicial: 1966
  • Paraules clau:

    Sistema cardiovascular--Malalties
    Cardiovascular diseases; Drug development; Epidemiology; Genetics; Mendelian randomization
    0735-1097
  • Documents:

  • Cerca a google

    Search to google scholar